


Accepted Manuscript

The neonatal window of opportunity – early priming for life

Harald Renz, MD, PhD, Becky D. Adkins, MD, Sina Bartfeld, PhD, Richard S. Blumberg, MD, PhD, Donna L. Farber, MD, PhD, Johan Garssen, MD, PhD, Peter Ghazal, MD, PhD, David J. Hackam, MD, Benjamin J. Marsland, MD, PhD, Kathy D. McCoy, MD, PhD, John Penders, MD, PhD, Immo Prinz, MD, PhD, Valerie Verhasselt, MD, PhD, Erika von Mutius, MD, MSc, Jeffrey N. Weiser, MD, Duane R. Wesemann, MD, PhD, Mathias W. Hornef, MD



PII: S0091-6749(17)31895-X

DOI: [10.1016/j.jaci.2017.11.019](https://doi.org/10.1016/j.jaci.2017.11.019)

Reference: YMAI 13161

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 8 June 2017

Revised Date: 23 October 2017

Accepted Date: 15 November 2017

Please cite this article as: Renz H, Adkins BD, Bartfeld S, Blumberg RS, Farber DL, Garssen J, Ghazal P, Hackam DJ, Marsland BJ, McCoy KD, Penders J, Prinz I, Verhasselt V, von Mutius E, Weiser JN, Wesemann DR, Hornef MW, The neonatal window of opportunity – early priming for life, *Journal of Allergy and Clinical Immunology* (2018), doi: 10.1016/j.jaci.2017.11.019.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 Paradigms and Perspectives

2
3
4 **The neonatal window of opportunity – early priming for life**

5
6
7 Harald Renz, MD, PhD¹; Becky D. Adkins, MD²; Sina Bartfeld, PhD³;
8 Richard S. Blumberg, MD, PhD⁴; Donna L. Farber, MD, PhD⁵; Johan Garssen, MD, PhD⁶;
9 Peter Ghazal, MD, PhD⁷; David J. Hackam, MD⁸; Benjamin J. Marsland, MD, PhD⁹;
10 Kathy D. McCoy, MD, PhD¹⁰; John Penders, MD, PhD¹¹; Immo Prinz, MD, PhD¹²;
11 Valerie Verhasselt, MD, PhD¹³; Erika von Mutius, MD, MSc¹⁴; Jeffrey N. Weiser, MD¹⁵;
12 Duane R. Wesemann, MD, PhD¹⁶; Mathias W. Hornef, MD¹⁷

13
14
15
16
17 1 University of Marburg, Germany

18 2 University of Miami, USA

19 3 University of Würzburg, Germany

20 4 Harvard University, USA

21 5 Columbia University Medical Center, USA

22 6 Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht
23 University, Utrecht, The Netherlands

24 7 University of Edinburgh, United Kingdom

25 8 Johns Hopkins University, Baltimore, USA

26 9 University Hospital of Lausanne, Switzerland

27 10 University of Calgary, Canada

28 11 Care and Public Health Research Institute (Caphri) & NUTRIM School for Nutrition and
29 Translational Research in Metabolism, Dept. of Medical Microbiology, Maastricht University,
30 The Netherlands

31 12 Hannover Medical School, Germany

32 13 Family Larsson-Rosenquist Foundation Chair in Human Lactology, School of Molecular
33 Science, University of Western Australia, Perth, Australia

34 14 Dr. von Hauner Children's Hospital, Ludwig Maximilians University Munich, Munich,
35 Germany, Comprehensive Pneumology Center Munich (CPC-M), Member of the German
36 Center for Lung Research

37 15 New York University School of Medicine, USA

38 16 Harvard University, Brigham and Women's Hospital, USA

39 17 RWTH University Hospital, Aachen, Germany

40
41
42
43
44
45
46 Correspondence to:

47 Harald Renz, MD

48 Institute of Laboratory Medicine

49 University of Marburg

50 Baldingerstr.

51 35043 Marburg, Germany

52 Phone: +49-6421-5866808

53 Fax: +49-6421-5866102

54 harald.renz@uk-gm.de

55

56 **List of abbreviations**

57

58

59

60 BCR B-cell receptor

61 COPD chronic obstructive pulmonary disease

62 EPEC enteropathogenic Escherichia coli

63 HDM house dust mite

64 IgD immunoglobulin D

65 IgM immunoglobulin M

66 IL interleukin

67 iNKT invariant natural killer T cells

68 LPS lipopolysaccharide

69 NCD non-communicable diseases

70 NEC necrotizing enterocolitis

71 NF- κ B nuclear factor kappa-light-chain-enhancer of activated B-cells

72 NKT cells natural killer T cells

73 RNA ribonucleic acid

74 TLR toll-like receptor

75 WHO World Health Organization

76

ACCEPTED MANUSCRIPT

77 **Abstract**

78

79 The concept of the neonatal window of opportunity assigns the early postnatal period a
80 critical role for life-long host-microbial and immune homeostasis. It is supported by
81 epidemiological evidence that links postnatal environmental exposure with disease
82 susceptibility and mechanisms in the neonate host that facilitate the postnatal transposition,
83 establish a stable microbiome and promote immune maturation. During the conference on
84 “The neonatal window of opportunity – early priming for life”, postnatal microbiome and
85 immune maturation, epidemiological evidence and fundamental mechanisms were discussed
86 to identify new targets for future preventive and interventional measures.

87

88

ACCEPTED MANUSCRIPT

89 From December 5-7, 2016, the Herrenhausen Conference “The neonatal window of
90 opportunity – early priming for life” took place at Hannover, Germany, sponsored by the
91 Volkswagen Foundation. The concept of the “neonatal window of opportunity”, i.e. a critical
92 non-redundant time frame in a newborn’s life during which environmental factors drive
93 immune and tissue maturation and influence the susceptibility to immune-mediated and other
94 diseases in adult life, was discussed.

95
96

97 Please note: An extended version of the manuscript can be found in the supplement.

98
99

100 ***Non-communicable diseases (NCD) as the grand challenge for*** 101 ***prevention***

102 Our body is exposed continuously to many danger signals. An effective immune system is
103 essential in order to protect and repair. Unbalanced immune reactivity seems to play a key
104 role in non-communicable diseases (NCDs) such as chronic pulmonary disease (COPD),
105 allergies, asthma, diabetes, cancer, and cardiovascular diseases as well as obesity (Johan
106 Garssen). Prevention is the grand challenge, since causal therapies for NCDs are still not
107 available and prevalences and incidences are currently on the rise.

108
109

110 ***Maternal/fetal/neonatal interaction***

111 The first “window of opportunity” in life is defined as the pre- or perinatal period. Particularly
112 in this period, microbial factors have a strong impact on the development of immune
113 responses. This includes the birth place and mode of delivery, breastfeeding, medication
114 (e.g. antibiotic use), introduction of solid foods, but also the exposure to siblings and pets
115 (John Penders). Challenging the immune tolerance of neonatal mice, germ-free mice
116 exhibited an exaggerated allergic response when exposed to allergens, as compared to
117 conventionally raised mice. Once their airway microbiome had formed after 2 post-natal
118 weeks, the mice were protected against this over-shooting allergic inflammation (Benjamin
119 Marsland) [1]. However, oral antigen administration in early life, even in the presence of
120 protective breast milk-derived factors, does not guarantee the induction of oral tolerance and
121 the prevention of allergic disease. This implies the necessity to identify limiting factors for oral
122 tolerance induction in early life (Valérie Verhasselt) [2].

123

124 Healthy nutrition during pregnancy and early life represents a key factor for proper immune
125 development. Human milk still remains the gold standard (Johan Garssen).

126

127

128 ***Development of immune tolerance in the neonatal period***

129 This goes hand in hand with the ontogeny of the enteric mucosal tissue and its influence on
130 the establishment of the enteric microbiota and long-term host-microbial homeostasis as well
131 as infection susceptibility. Age-dependently expressed features of the innate and adaptive
132 immune system that contribute to the postnatal acquisition of mucosal homeostasis and the
133 particular susceptibility of the neonate host to infection (Mathias Hornef) [3].

134

135

136 ***Early events and new insights into mechanisms***

137 *Streptococcus pneumoniae* is a leading cause of bacterial infection of the upper and lower
138 respiratory tract in children. This pathogen spreads to its host following acquisition of very
139 few organisms that quickly proliferate and dominate the niche in the upper respiratory tract.
140 This work established a **new paradigm for understanding pathogen transmission** and the
141 initial establishment of the colonizing microbiota in newborns (Jeffrey Weiser). This is also
142 influenced by the exposure to maternal microbiota metabolites in utero and in early life during
143 lactation that prepares the newborn for colonization with its own microbiota and sets the
144 baseline for a regulated immune system (Kathy McCoy) [4]. Important novel mechanisms are
145 summarized in figure 1. Neonates are often highly susceptible to intestinal pathogens. An
146 exception is seen after infection of murine neonates with *Yersinia enterocolitica*. Here,
147 multiple innate and adaptive components including (surprisingly) **CD8+ T lymphocytes**
148 **cells**, participate in protective immunity (Becky Adkins). **Natural killer T (NKT) cells** function
149 as a kind of checkpoint regulating the crosstalk between the microbiota and the immune
150 system. iNKT cells are resident cells of the gut mucosa that establish their niche during early
151 life when they home to and expand during a restricted period of neonatal life. Studies
152 performed in germ-free mice suggest a critical neonatal time period for the development and
153 proliferation of these immune cells (Richard Blumberg) [5]. **$\gamma\delta$ cells** in mice represent a first
154 line of defense with respect to both early in life during T-cell development and ontogeny as
155 well as in terms of mucosal tissue localization. The human neonate $\gamma\delta$ TCR repertoire
156 contains considerable frequencies of innate "public" TCR- δ sequences matching conserved
157 microbial structure (Immo Prinz). Symbiotic bacteria control the selection processes that
158 determine the antibody repertoire of **naïve B-cells** in neonatal mice. Interestingly, this
159 training event appears to be particularly influential during a narrow window of opportunity
160 after birth as commensal bacteria exposure of adult germ-free mice showed no effect on the

161 positive selection events (Duane Wesemann). Tissue specific **memory T cells** are
162 established as non-circulating resident memory T cells at various tissue sites in response to
163 microbial stimulation (Donna Farber) [6]. Necrotizing enterocolitis (NEC) is the leading cause
164 of death from gastrointestinal disease in premature infants and develops after an exuberant
165 proinflammatory response to the colonizing microbiota and this requires activation of the
166 lipopolysaccharide (LPS) receptor, **Toll like receptor (TLR) 4** (David Hackam) [7].

167
168

169 ***Role of environmental microbes***

170 Epidemiological studies show a strong correlation between early microbial exposure to
171 allergens and a reduced risk of hypersensitivity leading to asthma or hay fever later in life
172 (Erika von Mutius) [8]. The diversity and duration of microbial exposure early in life is
173 important for the development of tolerogenic immune functions. In this regard, mild
174 proinflammatory signals including IL-6 play a critical role to orchestrate early activation
175 signals (Harald Renz) [9].

176
177

178 ***New methods***

179 Stem cell-derived organoids represent a new three-dimensional model system of the gut
180 epithelium that allows the study of organ development, immune homeostasis and tissue
181 regeneration. Moreover, epithelial stem cell organoids now also open the possibilities to
182 study host-microbe-interaction (Sina Bartfeld).

183

184 System biology approaches applied to the global transcriptome generated from the RNA
185 isolated from a few drops of blood from pre-term babies have helped to reveal how
186 regulatory mechanisms determine the set-point for immune homeostasis in early life by
187 integrating specific immune and metabolic pathways that inter-patient differences can be
188 overcome and uncovered a novel immune-metabolic axis that accurately predicts sepsis in
189 neonates and infants. These studies lay the foundation for future translation of host pathways
190 in advancing diagnostic, prognostic, and therapeutic strategies for neonatal sepsis (Peter
191 Ghazal) [10].

192
193

194 ***Conclusion***

195

196 We are only starting to appreciate the critical impact of the postnatal period for lifelong health
197 and disease susceptibility. Recent discoveries provide the proof of principle, characterize the
198 critical time window(s) and identify underlying mechanisms. However, a number of important
199 questions remain: The cause-effect relationship between microbial exposure and health
200 needs to be established and the mechanisms operating during this “window of opportunity”
201 need to be elucidated. This must consequently lead to effective primary prevention
202 strategies. Future research will further deepen our understanding and extend from animal
203 models to human studies in order to develop interventional strategies to foster immune
204 homeostasis and prevent the development of diseases.

205

206

207

208 **Figure legend**

209 Figure 1 New mechanisms of microbe-immune interaction. For details please see text.

210

211 **Acknowledgements**

212

213 The conference and the preparation of this manuscript were supported by an unrestricted
214 grant of the Volkswagen Foundation, Hannover, Germany.

215

216 Johan Garssen receives grants from Nutricia-research foundation, Dutch government
217 funding (NWO, CCC,STW, RAAK/PRO, TKI), EU, and EDB.

218

219 Research in Mathias Hornef's laboratory is supported by the German Research Foundation
220 (SPP1656, SPP1580, IRTG1273 and Ho-2237/12-1) and the Niedersachsen Research
221 Network on Neuroinfectiology (N-RENNT).

222

223 Kathy McCoy is supported by a grant from the SNSF (SNSF310030_134902) and the
224 European Research Council (ERC, FP/2007-2013) Agreement no 281785.

225

226 John Penders is supported by a VIDI grant from the Netherlands Organisation for Scientific
227 Research and a Joint Programme Initiatives grant (Intestinal Microbiomics GI-MDH) within
228 the Healthy Diet for Healthy Living programme.

229

230 Immo Prinz is supported by the grant of the SFB900 (project B8).

231

232 Harald Renz is supported by the German Lung Center, Disease Area of Allergy and Asthma.

233

234 Erika von Mutius receives research grants from the German Research Foundation (DFG)
235 and the German Federal Ministry of Education and Research (BMBF)

236

237 We would like to thank Susanne Zapf for her excellent editorial assistance.

238


239 **References**

240

- 241 1. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, Nicod LP,
242 Lloyd CM, Marsland BJ. Lung microbiota promotes tolerance to allergens in neonates
243 via PD-L1. *Nat Med.* 2014; 20: 642-647.
- 244
- 245 2. Turfkruyer M, Rekima A, Macchiaverni P, Le Bourhis L, Muncan V, van den Brink GR,
246 Tulic MK, Verhasselt V. Oral tolerance is inefficient in neonatal mice due to a
247 physiological vitamin A deficiency. *Mucosal immunol.* 2016; 9, 479-491.
- 248
- 249 3. Torow N, Hornef MW. The Neonatal Window of Opportunity: Setting the Stage for
250 Life-Long Host-Microbial Interaction and Immune Homeostasis. *J Immunol.* 2017;
251 198: 557-563.
- 252
- 253 4. Gomez de Agüero M, Ganai-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H,
254 Steinert A, Heikenwalder M, Hapfelmeier S, Sauer U, McCoy KD, Macpherson AJ.
255 The maternal microbiota drives early postnatal innate immune development. *Science.*
256 2016; 351: 1296-1302.
- 257
- 258 5. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in
259 early life shapes the immune system. *Science.* 2016; 352: 539-544.
- 260
- 261 6. Zens KD, Chen JK, Guyer RS, Wu FL, Cvetkovski F, Miron M, Farber DL. Reduced
262 generation of lung tissue-resident memory T cells during infancy. *J Exp Med.* 2017
263 [Epub ahead of print].
- 264
- 265 7. Egan CE, Sodhi CP, Good M, Lin J, Jia H, Yamaguchi Y, Lu P, Ma C, Branca MF,
266 Weyandt S, Fulton WB, Niño DF, Prindle T Jr, Ozolek JA, Hackam DJ. Toll-like
267 receptor 4-mediated lymphocyte influx induces neonatal necrotizing enterocolitis. *J*
268 *Clin Invest.* 2016; 126: 495-508.
- 269
- 270 8. von Mutius E. Environmental factors influencing the development and progression of
271 pediatric asthma. *J Allergy Clin Immunol.* 2002; 109 (Suppl): S525-532.
- 272
- 273 9. Conrad ML, Ferstl R, Teich R, Brand S, Blümer N, Yildirim AO, Patrascan CC,
274 Hanuszkiewicz A, Akira S, Wagner H, Holst O, von Mutius E, Pfefferle PI, Kirschning
275 CJ, Garn H, Renz H. Maternal TLR signaling is required for prenatal asthma

- 276 protection by the nonpathogenic microbe *Acinetobacter lwoffii* F78. *J Exp Med.* 2009;
277 206: 2869-2877.
- 278
- 279 10. Smith CL, Dickinson P, Forster T, Craigh M, Ross A, Khondoker MR, France R,
280 Ivens A, Lynn DJ, Orme J, Jackson A, Lacaze P, Flanagan KL, Stenson BJ, Ghazal
281 P. Identification of a human neonatal immune-metabolic network associated with
282 bacterial infection. *Nat Commun.* 2014; 5: 4649.

ACCEPTED MANUSCRIPT

**Figure 1**